Programme SOM0044 for Parkinson’s Disease - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Programme SOM0044 for Parkinson’s Disease

10th February 2020

SOM0044 is a small molecule for the treatment of Parkinson’s disease.

Parkinson’s disease is a slowly progressive neurodegenerative disorder characterised by bradykinesia, rigidity, tremor at rest, shuffling gait and postural instability. The disease is caused by ageing, genetic and environmental factors. Symptoms usually appear around 60 years of age. Affects an estimated 10 million people worldwide. Available treatments are symptomatic, mainly involving dopaminergic agents for the control of motor function.

More About This Company